TCL Archive Congressional subcommittee criticizes NIH for lax conflict of interest policies. NIH Director Zerhouni promises change. The subcommittee has asked several NCI officials to testify at another hearing next week. By Cancer History Project May 14, 2004
TCL Archive Also in this 8-page issue: Intel Chairman Andrew Grove slams NCI director and cancer program for “wishful dreams” and “chemo speeches,” recommends moratorium on funding for cancer research. By Cancer History Project May 14, 2004
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. By Cancer History Project May 7, 2004
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. By Cancer History Project May 7, 2004
TCL Archive Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work. By Cancer History Project May 7, 2004
TCL Archive Michelle Le Beau named director of University of Chicago Cancer Research Center. By Cancer History Project May 7, 2004
Article Fran Visco tells the story of NBCC: “Women have declared war on breast cancer” By Cancer History Project
